1 Introduction
The International Olympic Committee (IOC)’s Framework on Fairness, Inclusion and Non-Discrimination on the Basis of Gender Identity and Sex Variations recommends but does not mandate that sport’s governing bodies follow the ten principles [1, 2] of: (1) inclusion, (2) prevention of harm, (3) non-discrimination, (4) fairness, (5) no presumption of advantage, (6) evidenced-based approach, (7) primacy of health and bodily autonomy, (8) stakeholder-centred approach, (9) right to privacy and (10) periodic reviews. As a result of principles 5, 6 and 8, the IOC proposes that sport’s governing bodies generate high-quality sport- and population-specific research to inform the development of any eligibility criteria applying across their relevant sports, disciplines and/or events [1, 2]. Currently, there is limited research on the effects of gender affirmation therapy on sports performance in well-trained transgender athletes, which constitutes a nascent but growing field. Scientific evidence ranges from the gold standard lab-based studies on athlete comparison groups to review articles that use a variety of methods to synthesise existing knowledge. One paper asserting policy relevance is the paper titled “Transgender Women in the Female Category of Sport, Perspectives on Testosterone Suppression and Performance Advantage” [3]. This publication by Hilton and Lundberg [3] has been prominently cited in numerous policies that exclude [4,5,6,7] and restrict [8] transgender women from the female category, with the suggestion that it offers relevant scientific evidence. Since it is up to individual international federations to decide which policy is best for their sport [1, 2], the goal of this letter is to help inform the physicians, scientists, athletes, international federations and other relevant stakeholders as to where this particular contribution to the literature falls in the hierarchy of evidence [9, 10] and to highlight concerns with the theoretical paradigms used by Hilton and Lundberg [3].
2 Hierarchy of Evidence: Narrative Reviews
Systematic reviews with accompanying meta-analyses are recognised as research designs offering high-quality evidence when conducted meticulously (Fig. 1). The goal of this type of research is to formulate an answer to a scientific issue on the basis of the synthesis of data that has been collected and analysed from a variety of different research studies. Systematic reviews and meta-analyses follow established standards, notably the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) criteria [11]. There are crucial distinctions between systematic and narrative reviews, which try to summarise previously published research on a certain topic but generally lack systematic ways to determine research eligibility, fail to conduct exhaustive searches, are prone to study bias and lack systematic ways to quantitatively assess patterns across studies in a field/topic of research. As a result, narrative reviews may be biased in their selection by excluding relevant research or favouring the findings of particular studies.
The evidence offered by Hilton and Lundberg [3] is in the form of a narrative review and not a systematic review, albeit the search criteria are provided in the supplemental material for Sect. 4, “is the male performance advantage lost when testosterone is suppressed in transgender women?” All previous literature searched in sections “2, the biological basis for sporting performance advantages in males,” and “3, sports performance differences between males and females” do not correspond to the scope of the article, which is transgender women in the female category of sport and seeks only to fuel the underlying assumption that cisgender male study populations are an appropriate substitute for transgender women (see Sect. 3). Furthermore, the literature utilised in Sects. 2 and 3 searches does not follow PRISMA [11] guidelines or follow principle 6, recommending that evidence from the field or the laboratory “be based on data collected from a demographic group that is consistent in gender and athletic engagement [1, 2],” making it difficult for readers to judge the transparency and scientific value of the process and review. This important distinction would allow the reader to assess the evidence presented in this article more accurately.
Given that there are currently very few transgender athletes competing in elite sports, and therefore even fewer related studies, the systematic review and meta-analysis strategy is at present impractical. Randomised control trials, the next highest-quality study design (Fig. 1), are also impractical in this area at present, leaving observational research, such as cohort studies [12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30], cross-sectional studies [28, 29, 31,32,33,34,35,36,37,38], case–control studies, case reports and case series, as the higher-ranking evidence base that could be considered by international federations (Fig. 1). Studies on the effects of gender affirming hormone treatment (GAHT) on performance-related metrics [39] will offer important insights; although results using sedentary transgender cohorts are useful, they cannot be directly extrapolated to transgender athletes. Data on transgender athletes are being generated [40, 41], but it will likely take more than 2 years to gather available observational information, which may not adequately address the question fully. Given the increasing prevalence of transgender persons in society [42, 43], systematic reviews and meta-analyses on transgender athletes may become available in the not-too-distant future. With the lack of an established systematic review approach, the evidence presented by Hilton and Lundberg [3] is limited to being characterised as low quality (Fig. 1 [9, 10]) and graded as an opinion piece with a low strength of evidence. In the interim, a comprehensive systematic evaluation on the impact of GAHT on sports performance in a sedentary transgender cohort [44] should be prioritised to guide sports organisations’ policy choices until sufficient transgender athlete data are acquired, as this is at least consistent in gender and fulfils some of principle 6 recommended by the IOC [1, 2].
3 Underlying Assumptions
The article by Hilton and Lundberg [3] has two primary theoretical misconceptions that undermine the accuracy and therefore the usefulness of the paper, first that cisgender male study populations are an appropriate substitute for transgender women, and second, that in the examination of sports performance, absolute data have a stronger level of evidence than relative data.
A starting assumption of Hilton and Lundberg [3] is that in the absence of research on transgender women, it is appropriate to rely on data collected from cisgender men to then compare the physiological and performance characteristics of cisgender men and women, as though the two groups are equivalent contrasting with IOC principle 6 [1, 2]. Existing research suggests that transgender women do not equate to cisgender men in either physiological [27] or performance terms [30]. In terms of physiology, the work of Wiik et al. [27] demonstrated that mean transgender women’s muscle volumes are already below the mean muscle volumes of cisgender men at baseline, with a similar outcome displayed in isometric torque levels. Furthermore, Van Caenegem et al. [28] showed that the lean mass was 6.8% less in pre-GAHT transgender women compared with control cisgender men (57.4 ± 8.7 kg versus 61.3 ± 6.8 kg). These results are noteworthy even though they are obtained from sedentary transgender women, and transgender women athletes may be closer to cisgender men as a starting point. However, this is unclear with physical performance measures, showing transgender women in the military had pre-GAHT upper body strength measures that were 12% lower (− 6 push ups, 95% CI − 20 to − 12) [30] than cisgender male controls, in comparison with sedentary transgender women who had pre-GAHT strength measures 15% lower (42 ± 9 versus 49 ± 6 N/kg) than cisgender male controls [28].
With research revealing the cumulative longitudinal physiological and performance effects of GAHT in sedentary transgender women, Hilton and Lundberg [3] highlight understanding gaps which include reductions in lean body mass that range from − 0.8% to − 5.4% [14,15,16, 18, 22, 24, 27,28,29, 44], reduced muscle cross-sectional area ranging from − 1.5% to − 11.7% [12, 24, 27, 28, 44], and decreases in the O2-carrying protein haemoglobin, ranging from − 3.4% to − 14% [15, 17, 19, 44]. Overall, the assumption that transgender women and cisgender men can simply be used as equivalent groups undermines the study’s assertion that it offers insights regarding the sporting capabilities of transgender women compared with cisgender women since it undertakes no such comparison.
The use of relative measures is foundational to sports performance testing. From undergraduate education onwards, sports scientists in the field normalise characteristics (e.g. height or weight) when concluding how an absolute measure (e.g. of muscular strength) will translate into actual athletic ability [45,46,47,48,49]. Despite this, Hilton and Lundberg’s [3] literature prioritise absolute rather than relative data, failing to normalise their results to either height or mass. In Table 4, Hilton and Lundberg [3] compare taller groups with shorter groups, which may account for a substantial portion of the variances in lean body mass or thigh area. Moreover, supplying reference female values generated from parallel cohorts of pre-GAHT transgender males rather than cisgender women creates a misleading impression for the reader. In Table 4, as previously discussed, sedentary transgender men are not the same as cisgender women athletes.
This issue reappears in Hilton and Lundberg’s article: 50% of the reported data on muscle strength, in Table 4 [3], is sourced from the test of absolute hand grip strength, despite absolute grip strength being a function of hand size [50]. Hilton and Lundberg [3] neither provide a relative measures analysis that is most relevant in understanding sports performance and aiding in the creation of sports policy, nor discuss the lack of relative performance measures as a limitation of these data. To properly determine whether athletic performance parameters are lost or gained in transgender women and men following the initiation of GAHT, any future research on the sporting ability of transgender athletes must, in addition to the non-corrected data, normalise for height, body mass and fat-free mass as appropriate. Interestingly, the authors do report that maximal oxygen uptake is 50% greater in cisgender men than cisgender women when reported in absolute terms and 25% when reported in relative terms, indicating that half of the differences is due to body mass alone.
Had Hilton and Lundberg [3] made their data available, as recommended by open science guidelines [51, 52] and the European Commission Research and Innovation Strategy 2020–2024 [53], the analyses might have been re-run by others in science to corroborate the authors’ findings and strengthen their analyses. Therefore, due to the priority of absolute data and the lack of open scientific methods, the analyses can only be characterised as limited.
4 Concluding Remarks
Hilton and Lundberg [3] are being widely cited by international federations to inform policy, yet as discussed here, the arguments and underlying assumptions presented in this paper are supported by the lowest level of evidence (Fig. 1) and do not align with the principles of the IOC Framework [1, 2], specifically principles 5, 6 and 8. It is unsurprising, therefore, that legal challenges have already been made as a result of the policies that this literature has provided as the evidence base [54, 55], which will serve to undermine the efforts and have negative repercussions for international federations, such as harming the confidence of its athletes, sponsors and the general public. To ensure both the integrity of the policy process and competition, international federations should reflect on the strength of the evidence in the studies they consider and utilise the highest-quality evidence available to make their decisions. Due to the growing number of transgender people in society, sub-elite transgender athletic data will be available imminently; however, due to the low participation rates of transgender athletes in elite sport and the growing number of exclusionary or limiting policies on their participation in elite sport, performance data on elite transgender athletes will likely not be readily available in the near future. Performance metrics are the most informative data, and research is currently underway using both sedentary [39, 56] and transgender [40, 41] athlete cohorts. While awaiting these data, international federations should not rush into making decisions informed by poor scientific evidence and should therefore prioritise following the ten principles of IOC framework [1, 2].
References
International Olympic Committee. Framework on fairness, inclusion and non-discrimination on the basis of gender identity and sex variations. 2021 [cited 2021 November, 29th]; Available from: https://stillmed.olympics.com/media/Documents/News/2021/11/IOC-Framework-Fairness-Inclusion-Non-discrimination-2021.pdf
Martowicz M, Budgett R, Pape M, Mascagni K, Engebretsen L, Dienstbach-Wech L, et al. Position statement: IOC framework on fairness, inclusion and non-discrimination on the basis of gender identity and sex variations. Br J Sports Med. 2023;57(1):26–32.
Hilton EN, Lundberg TR. Transgender women in the female category of sport: perspectives on testosterone suppression and performance advantage. Sports Med. 2020;51(1):199–214.
World Rugby. World Rugby Transgender Guideline. 2020 October 9th 2020 [cited 2021 November, 29th]; Available from: https://playerwelfare.worldrugby.org/?documentid=231
FINA. Policy on eligibility for the men's and women's competition categories. 2022 [cited F 3 and 4; Available from: https://resources.fina.org/fina/document/2022/06/19/525de003-51f4-47d3-8d5a-716dac5f77c7/FINA-INCLUSION-POLICY-AND-APPENDICES-FINAL-.pdf
British Triathlon. Transgender policy effective January 1st, 2023. FRG029 2022 [cited; Available from: https://www.britishtriathlon.org/britain/documents/about/edi/transgender-policy-effective-from-01-jan-2023.pdf
Sports Council Equality Group. SCEG Project for Review and Redraft of Guidance for Transgender Inclusion in Domestic Sport. 2020 [cited 20201 December, 6th]; Available from: https://equalityinsport.org/resources/index.html
Union Cycliste Internationale. Chapter V Eligibilty Regulations for Transgender Athletes. Part 13 Medical Rules 2022 [cited Article 13.5.013; Available from: https://assets.ctfassets.net/761l7gh5x5an/Et9v6Fyux9fWPDpKRGpY9/96949e5f7bbc8e34d536731c504ac96f/Modification_Transgender_Regulation_22_Juin_2022_ENG.pdf
Wallace SS, Barak G, Truong G, Parker MW. Hierarchy of evidence within the medical literature. Hosp Pediatr. 2022;12(8):745–50.
Evans D. Hierarchy of evidence: a framework for ranking evidence evaluating healthcare interventions. J Clin Nurs. 2003;12(1):77–84.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, The PRISMA, et al. statement: an updated guideline for reporting systematic reviews. BMJ. 2020;2021:372.
Elbers J, Asscheman H, Seidell J, Gooren LJ. Effects of sex steroid hormones on regional fat depots as assessed by magnetic resonance imaging in transsexuals. Am J Physiol Endocrinol Metab. 1999;276(2):E317–25.
Gooren LJ, Bunck MC. Transsexuals and competitive sports. Eur J Endocrinol. 2004;151(4):425–30.
Mueller A, Zollver H, Kronawitter D, Oppelt P, Claassen T, Hoffmann I, et al. Body composition and bone mineral density in male-to-female transsexuals during cross-sex hormone therapy using gonadotrophin-releasing hormone agonist. Exp Clin Endocrinol Diabetes. 2011;119(02):95–100.
Wierckx K, Van Caenegem E, Schreiner T, Haraldsen I, Fisher A, Toye K, et al. Cross-sex hormone therapy in trans persons is safe and effective at short-time follow-up: results from the European network for the investigation of gender incongruence. J Sex Med. 2014;11(8):1999–2011.
Gava G, Cerpolini S, Martelli V, Battista G, Seracchioli R, Meriggiola MC. Cyproterone acetate vs leuprolide acetate in combination with transdermal oestradiol in transwomen: a comparison of safety and effectiveness. Clin Endocrinol. 2016;85(2):239–46.
Auer MK, Cecil A, Roepke Y, Bultynck C, Pas C, Fuss J, et al. 12-months metabolic changes among gender dysphoric individuals under cross-sex hormone treatment: a targeted metabolomics study. Sci Rep. 2016;6(1):1–10.
Auer MK, Ebert T, Pietzner M, Defreyne J, Fuss J, Stalla GK, et al. Effects of sex hormone treatment on the metabolic syndrome in transgender individuals: focus on metabolic cytokines. J Clin Endocrinol Metab. 2018;103(2):790–802.
Jarin J, Pine-Twaddell E, Trotman G, Stevens J, Conard LA, Tefera E, et al. Cross-sex hormones and metabolic parameters in adolescents with gender dysphoria. Pediatrics. 2017;139:5.
Defreyne J, Vantomme B, Van Caenegem E, Wierckx K, De Blok C, Klaver M, et al. Prospective evaluation of hematocrit in gender-affirming hormone treatment: results from European Network for the Investigation of Gender Incongruence. Andrology. 2018;6(3):446–54.
Vita R, Settineri S, Liotta M, Benvenga S, Trimarchi F. Changes in hormonal and metabolic parameters in transgender subjects on cross-sex hormone therapy: a cohort study. Maturitas. 2018;107:92–6.
Klaver M, De Blok C, Wiepjes C, Nota NM, Dekker MJ, de Mutsert R, et al. Changes in regional body fat, lean body mass and body shape in trans persons using cross-sex hormonal therapy: results from a multicenter prospective study. Eur J Endocrinol. 2018;178(2):163–71.
Olson-Kennedy J, Okonta V, Clark LF, Belzer M. Physiologic response to gender-affirming hormones among transgender youth. J Adolesc Health. 2018;62(4):397–401.
Tack LJ, Craen M, Lapauw B, Goemaere S, Toye K, Kaufman J-M, et al. Proandrogenic and antiandrogenic progestins in transgender youth: differential effects on body composition and bone metabolism. J Clin Endocrinol Metab. 2018;103(6):2147–56.
Tack LJ, Heyse R, Craen M, Dhondt K, Bossche HV, Laridaen J, et al. Consecutive cyproterone acetate and estradiol treatment in late-pubertal transgender female adolescents. Journal of Sexual Medicine. 2017;14(5):747–57.
Scharff M, Wiepjes CM, Klaver M, Schreiner T, T’Sjoen G, den Heijer M. Change in grip strength in trans people and its association with lean body mass and bone density. Endocr Connect. 2019;8(7):1020–8.
Wiik A, Lundberg T, Rullman E, Andersson D, Holmberg M, Mandić M, et al. Muscle strength, size, and composition following 12 months of gender-affirming treatment in transgender individuals. J Clin Endocrinol Metab. 2020;105:3.
Van Caenegem E, Wierckx K, Taes Y, Schreiner T, Vandewalle S, Toye K, et al. Preservation of volumetric bone density and geometry in trans women during cross-sex hormonal therapy: a prospective observational study. Osteoporos Int. 2015;26(1):35–47.
Haraldsen I, Haug E, Falch J, Egeland T, Opjordsmoen S. Cross-sex pattern of bone mineral density in early onset gender identity disorder. Horm Behav. 2007;52(3):334–43.
Roberts TA, Smalley J, Ahrendt D. Effect of gender affirming hormones on athletic performance in transwomen and transmen: implications for sporting organisations and legislators. Br J Sports Med. 2020;55(11):557–83.
SoRelle JA, Jiao R, Gao E, Veazey J, Frame I, Quinn AM, et al. Impact of hormone therapy on laboratory values in transgender patients. Clin Chem. 2019;65(1):170–9.
Greene DN, McPherson GW, Rongitsch J, Imborek KL, Schmidt RL, Humble RM, et al. Hematology reference intervals for transgender adults on stable hormone therapy. Clin Chim Acta. 2019;492:84–90.
Roberts TK, Kraft CS, French D, Ji W, Wu AH, Tangpricha V, et al. Interpreting laboratory results in transgender patients on hormone therapy. Am J Med. 2014;127(2):159–62.
Lapauw B, Taes Y, Simoens S, Van Caenegem E, Weyers S, Goemaere S, et al. Body composition, volumetric and areal bone parameters in male-to-female transsexual persons. Bone. 2008;43(6):1016–21.
Jain J, Kwan D, Forcier M. Medroxyprogesterone acetate in gender-affirming therapy for transwomen: results from a retrospective study. J Clin Endocrinol Metab. 2019;104(11):5148–56.
Alvares LA, Santos MR, Souza FR, Santos LM, Mendonca BB, Alves MJNN, et al. First evidence of cardiopulmonary adaptation to physical effort in transgender women after long-term hormone therapy: a cross-sectional study. J Endocr Soc. 2021;5(1):790–1.
Alvares LA, Santos MR, Souza FR, Santos LM, Ramos HA, Mendonca BB, et al. Muscle strength in transgender women after long-term hormone therapy: a cross-sectional study. J Endocr Soc. 2021;5(1):792.
Alvares LAM, Santos MR, Souza FR, Santos LM, de Mendonça BB, Costa EMF, et al. Cardiopulmonary capacity and muscle strength in transgender women on long-term gender-affirming hormone therapy: a cross-sectional study. Br J Sports Med. 2022;56(22):1292–8.
Jones PR, Voisin S, Nolan BJ, Landen S, Jacques M, Newell B, et al. Uncovering the effects of gender affirming hormone therapy on skeletal muscle and epigenetics: protocol for a prospective matched cohort study in transgender individuals (the GAME study). BMJ Open. 2022;12(5): e060869.
Hamilton BR, Lima G, Barrett J, Seal L, Kolliari-Turner A, Guppy F, et al. The effects of gender affirming treatment on the sporting performance and muscle memory of transgender athletes. A Protocol for The Tavistock Transgender Athlete Study. SportRxiv. 2021;1:1.
Hamilton B, Comeras-Chueca C, Bush P, Seal L, Guppy F, Pitsiladis Y. Sporting performance of athletes of the gender spectrum: a cross-sectional comparison study protocol. SportRxiv. 2022;1:1.
Aitken M, Steensma TD, Blanchard R, VanderLaan DP, Wood H, Fuentes A, et al. Evidence for an altered sex ratio in clinic-referred adolescents with gender dysphoria. J Sex Med. 2015;12(3):756–63.
De Vries A, Kreukels B, T’sjoen G, Ålgars M, Mattila A. Increase of referrals to gender identity clinics: a European trend. Transgend Healthcare Europe Book Abstracts. 2015;2:10.
Harper J, O’Donnell E, Sorouri Khorashad B, McDermott H, Witcomb GL. How does hormone transition in transgender women change body composition, muscle strength and haemoglobin? Systematic review with a focus on the implications for sport participation. Br J Sports Med. 2021;55(15):865–72.
Schneiker KT, Fyfe JJ, Teo SYM, Bishop DJ. Comparative effects of contrast training and progressive resistance training on strength and power-related measures in subelite Australian rules football players. J Strength Condit Res. 2023;2:2.
Letter RT, Dwyer DB, Drinkwater EJ, Feros SA. The physical qualities of elite Australian pace bowlers: typical characteristics and longitudinal changes in men and women. Int J Sports Physiol Perform. 2022;17(12):1691–7.
Folhes O, Reis VM, Marques DL, Neiva HP, Marques MC. Maximum isometric and dynamic strength of mixed martial arts athletes according to weight class and competitive level. Int J Environ Res Public Health. 2022;19:14.
Andersen E, Lockie RG, Dawes JJ. Relationship of absolute and relative lower-body strength to predictors of athletic performance in collegiate women soccer players. Sports. 2018;6(4):106.
Suchomel TJ, Nimphius S, Stone MH. The importance of muscular strength in athletic performance. Sports Med. 2016;46:1419–49.
Alahmari K, Kakaraparthi V, Reddy R, Silvian PS, Ahmad I, Rengaramanujam K. Percentage difference of hand dimensions and their correlation with hand grip and pinch strength among schoolchildren in Saudi Arabia. Niger J Clin Pract. 2019;22(10):1356.
van der Zee T, Reich J. Open education science. AERA Open. 2018;4(3):2332858418787466.
Crüwell S, van Doorn J, Etz A, Makel MC, Moshontz H, Niebaum J, et al. 7 easy steps to open science: an annotated reading list. 2018.
European Commission. The EU's Open Science Policy. Open Science 2023 [cited 2023 April 27th]; Available from: https://research-and-innovation.ec.europa.eu/strategy/strategy-2020-2024/our-digital-future/open-science_en
Tomas F. RFU hit by legal action over transgender women ban. 2022 [cited; Available from: https://www.telegraph.co.uk/rugby-union/2022/09/03/exclusive-rfu-hit-legal-action-transgender-women-ban/
American Civil Liberties Union. Soule et al., V. CT Association of Schools et al., 2022 November 23, 2022 [cited; Available from: https://www.aclu.org/cases/soule-et-al-v-ct-association-schools-et-al
Lehmann Christensen L, Glintborg D, Taulbjerg Kristensen T, Diederichsen A, T’Sjoen G, Frystyk J, et al. Masculinising testosterone treatment and effects on preclinical cardiovascular disease, muscle strength and power, aggression, physical fitness and respiratory function in transgender men: protocol for a 10-year, prospective, observational cohort study in Denmark at the Body Identity Clinic (BIC). BMJ Open. 2020;10(12): e045714.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Author contributions
The idea, material preparation, literature review, reporting and critical revision of the work were performed by Blair Hamilton, Fergus Guppy and Yannis Pitsiladis. Blair Hamilton wrote the first draft of the manuscript. Fergus Guppy and Yannis Pitsiladis critically revised subsequent versions of the manuscript until all authors were able to approve the final manuscript.
Funding
The writing of this manuscript was not funded.
Conflict of Interest
Yannis Pitsiladis is a member of the IOC Medical and Scientific Commission, which has recently published articles and framework documents on the topic. Blair Hamilton and Fergus Guppy have recently published articles on the topic on behalf of International Federation of Sports Medicine (FIMS). All authors declare that they have no further conflict of interest or competing interests.
Ethics approval
No ethics approval was required for this manuscript.
Rights and permissions
About this article
Cite this article
Hamilton, B., Guppy, F. & Pitsiladis, Y. Comment on: “Transgender Women in the Female Category of Sport: Perspectives on Testosterone Suppression and Performance Advantage”. Sports Med 54, 237–242 (2024). https://doi.org/10.1007/s40279-023-01928-8
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40279-023-01928-8